Trial Profile
Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms FITZROY
- Sponsors Galapagos NV
- 01 Aug 2022 Results assessing effects of JAK1-Preferential Inhibitor Filgotinib on circulating biomarkers and whole blood Genes/Pathways using data from this study published in the Inflammatory Bowel Diseases
- 19 May 2020 Results, analysis of baseline correlation of whole blood transcriptome pathway activities with clinical disease indexes and circulating cytokines, published in Gastroenterology in conjunction with Digestive Disease Week 2020
- 19 May 2020 Results of poct-hoc analysis assessing the effect of FIL on molecular markers of JAK1-related signalling (STAT1 & STAT3 phosphorylation) within epithelium and non-epithelium regions of intestinal mucosa and explore their correlation to histologic and endoscopic indices published at the Digestive Disease Week 2020